Skip to main content

Table 1 Patient characteristics

From: Highly multiplexed quantifications of 299 somatic mutations in colorectal cancer patients by automated MALDI-TOF mass spectrometry

Characteristic All patients
(N = 229) (%)
Frozen tissue cohort
(N = 183) (%)
FFPE tissue cohort
(N = 46) (%)
Age - no.
  < 50 20 (8.7) 17 (9.3) 3 (6.5)
 50–70 124 (54.1) 101 (55.2) 23 (50.0)
  > 70 85 (37.2) 65 (35.3) 20 (43.5)
Gender - no.
 Male 145 (63.3) 113 (61.7) 32 (69.6)
 Female 84 (36.7) 70 (38.3) 14 (30.4)
Clinical stage - no.
 I 53 (23.2) 34 (18.6) 19 (41.3)
 II 69 (30.1) 59 (32.3) 10 (21.7)
 III 82 (35.8) 71 (38.8) 11 (24.0)
 IV 25 (10.9) 19 (10.4) 6 (13.0)
Location sampled - no.
 Rectum 177 (77.3) 140 (76.5) 37 (80.5)
 Left Colon 19 (8.3) 17 (9.3) 2 (4.3)
 Right Colon 21 (9.2) 16 (8.7) 5 (10.9)
 Rectosigmoid Junction 12 (5.2) 10 (5.5) 2 (4.3)
Differentiation - no.
 Well 13 (5.7) 12 (6.6) 1 (2.2)
 Moderate 180 (78.6) 145 (79.2) 35 (76.0)
 Poor 28 (12.2) 19 (10.4) 9 (19.6)
 Unknowna 8 (3.5) 7 (3.8) 1 (2.2)
Metastatic sites - no.
 Liver only 19 (8.3) 15 (8.2) 4 (8.7)
 Lung only 2 (0.9) 1 (0.5) 1 (2.2)
 Liver and Lung 1 (0.4) 1 (0.5) 0 (0.0)
 Bladder 1 (0.4) 1 (0.5) 0 (0.0)
 Brain 1 (0.4) 1 (0.5) 0 (0.0)
Treatment after surgery - no.
 With adjuvant therapy 129 (56.3) 109 (59.6) 20 (43.5)
 Without adjuvant therapy 96 (42.0) 74 (40.4) 22 (47.8)
 NA 4 (1.7) 0 (0.0) 4 (8.7)
Tumor size - cm
 Median (range) 4(1.5–13) 4 (1.5–13) 4(1.5–12)
CEA - ng/mL
 0.0–5.0 150 (65.5) 125 (68.3) 25 (54.3)
  > 5.0 74 (32.3) 53 (29.0) 21 (45.6)
 N/A 5 (2.2) 5 (2.7) 0 (0.0)
  1. aReported as mucinous adenocarcinomas
  2. N/A not available